

Clinical Policy: Sepiapterin (Sephience)

Reference Number: CP.PHAR.708

Effective Date: 07.28.25

Last Review Date: 05.26

Line of Business: Commercial, HIM/ICHRA, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Sepiapterin (Sephience[™]) is a phenylalanine hydroxylase (PAH) activator.

FDA Approved Indication(s)

Sephience is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). Sephience is to be used in conjunction with a phenylalanine (Phe)-restricted diet.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Sephience is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Phenylketonuria (must meet all):**

1. Diagnosis of HPA due to PKU;
 2. Prescribed by or in consultation with an endocrinologist, metabolic disease specialist, or genetic disease specialist;
 3. Recent (within 90 days) Phe blood level is ≥ 360 $\mu\text{mol/L}$;
 4. Member is currently adherent on a Phe-restricted diet and will continue this diet during treatment with Sephience;
 5. Failure of generic sapropterin (Kuvan[®]) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;*
- *For Illinois HIM requests, the step therapy requirements above do not apply as of 1/1/2026 per IL HB 5395.*
6. Sephience is not prescribed concurrently with sapropterin (Kuvan, Javygtor, Zelvysia) or Palynziq[™];
 7. Documentation of member's current weight (in kg);
 8. Dose does not exceed 60 mg/kg per day.

Approval duration: 6 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):

- a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
- b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Phenylketonuria (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as demonstrated by a reduction in Phe blood levels since initiation of therapy;
3. Member is currently adherent on a Phe-restricted diet and will continue this diet during treatment with Sepsience;
4. Sepsience is not prescribed concurrently with sapropterin (Kuvan, Javygtor, Zelvyasia) or Palynziq;
5. Documentation of member's current weight (in kg);
6. If request is for a dose increase, new dose does not exceed 60 mg/kg per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND

criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

HPA: hyperphenylalaninemia

Phe: phenylalanine

PKU: phenylketonuria

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
sapropterin (Kuvan, Javygtor, Zelvysia)	Age 1 month to ≤ 6 years (starting dose): 10 mg/kg PO QD Age ≥ 7 years (starting dose): 10 to 20 mg/kg PO QD	20 mg/kg/day

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

None reported

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
PKU	Age less than 6 months: 7.5 mg/kg PO QD Age 6 months to less than 1 year: 15 mg/kg PO QD Age 1 year to less than 2 years: 30 mg/kg PO QD Age ≥ 2 years: 60 mg/kg PO QD For calculated daily doses less than 1,000 mg, prepare Sephience as a liquid mixture with a final concentration of 25 mg/mL. Round the dose <i>up</i> to the nearest 250 mg to determine the number of Sephience packets required. For calculated daily doses 1,000 mg or greater, round the dose to the nearest 250 mg to determine the number of Sephience packets required.	60 mg/kg/day

VI. Product Availability

Oral powder: 250 mg, 1,000 mg

VII. References

1. Sephience Prescribing Information. Warren, NJ: PTC Therapeutics, Inc.; July 2025. Available at: www.sephience.com. Accessed: March 5, 2026.
2. Muntau AC, Longo N, Ezgu F, et al. Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): Results of an international, phase 3, randomised, double-blind, placebo-controlled trial. *Lancet*. Oct 2024; 404(10460): 1333-1345.
3. Smith WE, Berry SA, Bloom K, et al. Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2025;27(1): Article 101289. <https://doi.org/10.1016/j.gim.2024.101289>.
4. Van Wegberg AMJ, MacDonald A, Ahring K, et al. European guidelines on diagnosis and treatment of phenylketonuria: first revision. *Molecular Genetics and Metabolism*. June 2025;145(2):109125. <https://doi.org/10.1016/j.ymgme.2025.109125>.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created pre-emptively	12.03.24	02.25
RT4: Drug is now FDA approved – criteria updated per FDA labeling: updated diagnosis to specify HPA due to PKU (rather than just PKU) to reflect approved indication; removed age limit for sapropterin redirection as both Sephience and sapropterin are approved for the same ages; added a requirement for documentation of member’s current weight for dose calculation purposes; references reviewed and updated.	08.07.25	
1Q 2026 annual review: added adherent to Phe-restricted diet per labeling and plan feedback; added step therapy bypass for IL HB 5395; references reviewed and updated.	11.07.25	02.26
2Q 2026 annual review: bringing forward to align with the annual review cycle for Kuvan and Palynziq; references reviewed and updated. Added ICHRA line of business.	04.10.26	05.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in

developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2025 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international

copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.